We chat with Dr. Paul Szumita and Dr. Jeffrey Pearson, both of Brigham and Women’s Hospital in Boston, MA about updates on the use of antiviral therapies, anti-inflammatory management, as well as supportive care in patients with COVID-19. For more on this topic, please see https://elearning.ashp.org/COVID-19 and Expert Insight articles at https://ashpadvantage.com/expert-insight/.
Paul M. Szumita, Pharm.D., BCPS, BCCCP, FASHP, FCCM, is Director of Clinical Pharmacy Services and Program Director of the PGY-2 Critical Care pharmacy residency at Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Szumita is a fellow in the American College of Critical Care Medicine and ASHP. Dr. Szumita is responsible for directing clinical programs aimed at optimizing pharmacotherapy and improving patient outcomes. He has more than 70 peer-reviewed publications and serves on several committees focused on improving clinical practice at the local, regional, and national level, including the program advisory board for the ASHP Critical Care Pharmacy Specialty Board Examination Review Course.
Jeffrey C. Pearson, Pharm.D., BCIDP, is Clinical Pharmacy Specialist in Infectious Diseases at Brigham and Women’s Hospital in Boston, Massachusetts, where he serves as the point person for the hospital’s antimicrobial stewardship program and COVID-19 therapeutic guidelines. Dr. Pearson received his Doctor of Pharmacy degree from Northeastern University in 2014. He completed his PGY-1 residency at Mount Auburn Hospital in Cambridge, Massachusetts and PGY-2 residency in Infectious Diseases at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He can be reached on Twitter at @jeffpears0n.